ConductScience.org, home

Paper25908682

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Mulligan K and 19 others. Clin Infect Dis, 2015. Cited by 131 papers, by iCite.

Cite this record

ConductScience Library. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Papers, record 25908682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25908682

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2015
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
131
iCite
Relative citation ratio, by iCite
5.18
iCite
Revised in PubMed
2026-05-18
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mulligan KKathleen
2Glidden DVDavid V
3Anderson PLPeter L
4Liu AAlbert
5McMahan VVanessa
6Gonzales PPedro
7Ramirez-Cardich MEMaria Esther
8Namwongprom SSirianong
9Chodacki PPiotr
10de Mendonca LMLaura Maria Carvalo
11Wang FFurong
12Lama JRJavier R
13Chariyalertsak SSuwat
14Guanira JVJuan Vicente
15Buchbinder SSusan
16Bekker LGLinda-Gail
17Schechter MMauro
18Veloso VGValdilea G
19Grant RMRobert M
20Preexposure Prophylaxis Initiative Study TeamGroup

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
Bone DensityMajor topic
ChemopreventionMajor topic
EmtricitabineMajor topic
HIV InfectionsMajor topic
TenofovirMajor topic
Absorptiometry, Photon
Administration, Oral
Adolescent
Adult
Cytoplasm
Double-Blind Method
Female
Humans
Male
Middle Aged
Placebos
Plasma
Young Adult

Source PubMed

Download CSV of topics

Grants9

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
UM1 AI069476NIAID NIH HHSUnited StatesUM1AI069476PubMed and NIHNIH RePORTER
U01 AI84735NIAID NIH HHSUnited StatesU01AI084735PubMed and NIHNIH RePORTER
U01 AI084735NIAID NIH HHSUnited StatesU01AI084735PubMed and NIHNIH RePORTER
R01 AI118575NIAID NIH HHSUnited StatesR01AI118575PubMedNIH RePORTER
R03 AI120819NIAID NIH HHSUnited StatesR03AI120819PubMed and NIHNIH RePORTER
UM1 AI069496NIAID NIH HHSUnited StatesUM1AI069496PubMed and NIHNIH RePORTER
U01AI64002NIAID NIH HHSUnited StatesU01AI064002PubMed and NIHNIH RePORTER
UL1 TR000004NCATS NIH HHSUnited StatesUL1TR000004PubMed and NIHNIH RePORTER
U01 AI064002NIAID NIH HHSUnited StatesU01AI064002PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00458393Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in MenDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in25908681Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis.https://conductscience.org/library/papers/25908681

Source PubMed

Download CSV of comments and corrections

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122096407Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.HIV AIDS (Auckl)2011https://conductscience.org/library/papers/22096407PubMed
219842973Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.Clin Infect Dis2009https://conductscience.org/library/papers/19842973PubMed
319398921
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
J Acquir Immune Defic Syndr2009https://conductscience.org/library/papers/19398921PubMed
419512937Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.J Acquir Immune Defic Syndr2009https://conductscience.org/library/papers/19512937PubMed
521522014Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.J Acquir Immune Defic Syndr2011https://conductscience.org/library/papers/21522014PubMed
622784038Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.N Engl J Med2012https://conductscience.org/library/papers/22784038PubMed
722784037Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.N Engl J Med2012https://conductscience.org/library/papers/22784037PubMed
824625530Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.PLoS One2014https://conductscience.org/library/papers/24625530PubMed
99351170Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.Stat Med1997https://conductscience.org/library/papers/9351170PubMed
1020683316Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.AIDS2010https://conductscience.org/library/papers/20683316PubMed
1122972843Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Sci Transl Med2012https://conductscience.org/library/papers/22972843PubMed
1225296097
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.
J Acquir Immune Defic Syndr2015https://conductscience.org/library/papers/25296097PubMed
1319874178Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.J Infect Dis2009https://conductscience.org/library/papers/19874178PubMed
1417053350A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.AIDS2006https://conductscience.org/library/papers/17053350PubMed
1515293701Prevention and management of osteoporosis.World Health Organ Tech Rep Ser2003https://conductscience.org/library/papers/15293701PubMed
1623148289Low bone mineral density, regardless of HIV status, in men who have sex with men.J Infect Dis2013https://conductscience.org/library/papers/23148289PubMed
1725170938
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
PLoS One2014https://conductscience.org/library/papers/25170938PubMed
1818573931Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18573931PubMed
1922819139Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy.J Clin Densitom2012https://conductscience.org/library/papers/22819139PubMed
2018793764International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions.Bone2008https://conductscience.org/library/papers/18793764PubMed

See all 37 referencesDownload CSV of references

Cited by87

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 131 citations.

PMIDTitleJournalYearIn PapersSource
42579882HIV Pre-Exposure Prophylaxis Use Among South Asian Sexual Minority Men in the United States: Pilot Web-Based Survey Study.JMIR Form Res2026https://conductscience.org/library/papers/42579882PubMed
42141514
Renal function in African women receiving tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial.
HIV Med2026https://conductscience.org/library/papers/42141514PubMed
41891184Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV.AIDS2026https://conductscience.org/library/papers/41891184PubMed
41797349Bone Health in People Living with HIV: From Pathophysiology to Practical Management.Infect Chemother2026https://conductscience.org/library/papers/41797349PubMed
41040064Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025.Euro Surveill2025https://conductscience.org/library/papers/41040064PubMed
40632108Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy.J Pediatric Infect Dis Soc2025https://conductscience.org/library/papers/40632108PubMed
40071257Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status.Infez Med2025https://conductscience.org/library/papers/40071257PubMed
39528419In-utero exposure to tenofovir-containing pre-exposure prophylaxis and bone mineral content in HIV-unexposed infants in South Africa.J Int AIDS Soc2024https://conductscience.org/library/papers/39528419PubMed
38484128
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
Clin Infect Dis2024https://conductscience.org/library/papers/38484128PubMed
38399361Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density-A Scoping Review of the Literature.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38399361PubMed
37971137Cytogenetic changes in oral mucosa cells from individuals submitted to oral human immunodeficiency virus pre-exposure prophylaxis use.Rev Assoc Med Bras (1992)2023https://conductscience.org/library/papers/37971137PubMed
37861643Pre-exposure prophylaxis for prevention of HIV infection.Singapore Med J2023https://conductscience.org/library/papers/37861643PubMed
35687192
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
AIDS Behav2022https://conductscience.org/library/papers/35687192PubMed
35355890Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.Open Forum Infect Dis2022https://conductscience.org/library/papers/35355890PubMed
34992111
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
BMJ Open2022https://conductscience.org/library/papers/34992111PubMed
34791296Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.J Antimicrob Chemother2022https://conductscience.org/library/papers/34791296PubMed
34697493HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.Nat Rev Urol2022https://conductscience.org/library/papers/34697493PubMed
34482350Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.AIDS2021https://conductscience.org/library/papers/34482350PubMed
34482349The combined effects of age and HIV on the anatomic distribution of cortical and cancellous bone in the femoral neck among men and women.AIDS2021https://conductscience.org/library/papers/34482349PubMed
34075504Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature.Arch Sex Behav2021https://conductscience.org/library/papers/34075504PubMed

See all 87 cited byDownload CSV of cited by

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
TENOFOVIR DISOPROXIL FUMARATECHEMBL1486Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1486ChEMBL
EMTRICITABINE, (+/-)-CHEMBL161381Derived from the trial1https://conductscience.org/library/drugs/CHEMBL161381ChEMBL
EMTRICITABINECHEMBL885Derived from the trial1https://conductscience.org/library/drugs/CHEMBL885ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25908682

GET https://conductscience.org/api/papers/v1/25908682/references?page=2